Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Will Genus's Gene-Edited Pig Bring Home Bigger Profits?

The latest decline reflects continued caution following FY2026 results in September, when Genus reported a 35% rise in adjusted profit before tax and a £60 million buyback, but forecast only moderate growth in FY2027 weighted towards the second half. The shares fell around 6.5% …

Divya Sood | 02 November 2026

Oxford BioDynamics Plc (LSE:OBD) in AIM Spotlight: What Could Shape the Next Share-Price Move?

Key sector variables include clinical or product milestones, reimbursement, regulatory pathways and commercial uptake. Investors may respond differently to progress on individual projects and evidence of recurring earnings.

Ankur Sharma | 02 November 2026

Optima Health PLC (LSE:OPT) in AIM Spotlight: What Could Shape the Next Share-Price Move?

Key sector variables include clinical or product milestones, reimbursement, regulatory pathways and commercial uptake. Investors may respond differently to progress on individual projects and evidence of recurring earnings.

Ankur Sharma | 02 November 2026

RUA Life Sciences Plc (LSE:RUA) in AIM Spotlight: What Could Shape the Next Share-Price Move?

Key sector variables include clinical or product milestones, reimbursement, regulatory pathways and commercial uptake. Investors may respond differently to progress on individual projects and evidence of recurring earnings.

Ankur Sharma | 02 November 2026

Shield Therapeutics Plc (LSE:STX) in AIM Spotlight: What Could Shape the Next Share-Price Move?

Key sector variables include clinical or product milestones, reimbursement, regulatory pathways and commercial uptake. Investors may respond differently to progress on individual projects and evidence of recurring earnings.

Ankur Sharma | 02 November 2026

Verici Dx Plc (LSE:VRCI) in AIM Spotlight: What Could Shape the Next Share-Price Move?

Key sector variables include clinical or product milestones, reimbursement, regulatory pathways and commercial uptake. Investors may respond differently to progress on individual projects and evidence of recurring earnings.

Ankur Sharma | 02 November 2026

Eden Biosolutions PLC (LSE:EDEN) in AIM Spotlight: What Could Shape the Next Share-Price Move?

Key sector variables include clinical or product milestones, reimbursement, regulatory pathways and commercial uptake. Investors may respond differently to progress on individual projects and evidence of recurring earnings.

Ankur Sharma | 02 November 2026

Why AstraZeneca (LSE:AZN) surged on the FTSE 100: a quarterly beat, reaffirmed guidance and a new savings programme

The headline numbers explain the enthusiasm. Pretax profit rose 22% in the quarter, whileRevenuegrew by between 6.7% and 7%, depending on the measure reported. Management also reaffirmed its full-year guidance, which gave investors reassurance that the good quarter was not a one-off and that …

Ankur Sharma | 02 November 2026

Why GSK (LSE:GSK) climbed on the FTSE 100: pharma stocks rose alongside AstraZeneca's (LSE:AZN) results-driven surge

GSK is one of Britain's largest drugmakers, with aBusinessbuilt around prescription medicines and vaccines. Companies of this type are often treated as defensive holdings becauseDemandfor medicines is less sensitive to the economic cycle than demand for many other goods and services. That reputation tends …

Ankur Sharma | 02 November 2026

10 UK Healthcare Growth Stocks in Focus for November 2026 Across the FTSE and AIM Markets

The selection spans FTSE-listed businesses and AIM growth candidates rather than a ranking by daily price gains.

Ankur Sharma | 02 November 2026
Support

Hi! How can we help you today?

Loading…